Metabolic HealthSurgery vs. Ozempic: Why Bariatric Procedures Still Win for Durable Weight Loss
Nearly one billion adults worldwide now live with obesity, dramatically raising their risk of type 2 diabetes, cardiovascular disease, cancer, and premature death. Bariatric surgery remains the most effective and durable treatment, yet fewer than 1% of eligible patients receive it. The explosion of GLP-1 receptor agonists like semaglutide has raised urgent questions about whether surgery is still necessary. This review from Brigham and Women's Hospital synthesizes current evidence and concludes that surgery still produces greater and more lasting weight loss than drugs alone. However, the two approaches need not compete: GLP-1 drugs can optimize patients before surgery or rescue those with post-surgical weight regain. The authors advocate for a chronic-disease management model integrating pharmacotherapy, surgery, and multidisciplinary care tailored to each individual's needs and circumstances.
